An introduction to the metabolic determinants of anthracycline cardiotoxicity

Cardiovascular Toxicology

Volumn 7, Issue 2, 2007, Pages 80-85

  Menna, Pierantonio ^a,b   Recalcati, Stefania ^c   Cairo, Gaetano ^c   Minotti, Giorgio ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Anthracyclines; Cardiotoxicity; Doxorubicin; Iron; Metabolism

Indexed keywords

5 IMINODAUNORUBICIN; 7 DEOXYDOXORUBICINOL; ANTHRACYCLINE; C 13 DEOXYDOXORUBICIN; DOCUSATE SODIUM; DOXORUBICIN; DOXORUBICINOL; FERRITIN; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; RAZOXANE; REACTIVE OXYGEN METABOLITE; SABARUBICIN; SEMIQUINONE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ELECTRONS; HEART DISEASES; HUMANS; IRON; MYOCARDIUM; OXIDATION-REDUCTION;

EID: 34548301536     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-007-0011-7     Document Type: Conference Paper

References (33)

1. Meissner, K., Sperker, B., Karsten, C, Zu Schwabedissen, H. M., Seeland, U., Bohm, M., Bien, S., Dazert, P., Kunert-Keil, C., Vogelgesang, S., Warzok, R., Siegmund, W., Cascorbi, I., Wendt, M., & Kroemer, H. K. (2002). Expression and localization of P-glycoprotein in human heart: Effects of cardiomyopathy. The Journal of Histochemistry and Cytochemistry, 50, 1351-1356.
2. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185-229.
3. Cusack, B. J., Young, S. P., Driskell, J., & Olson, R. D. (1993). Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemotherapy and Pharmacology, 32, 53-58.
4. Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G., & Cairo, G. (2004). Doxorubicin cardiotoxicity and the control of iron metabolism: Quinone dependent and independent mechanisms. Methods in Enzymology, 378, 340-361.
5. Menna, P., Salvatorelli, E., Giampietro, R., Liberi, G., Teodori, G., Calafiore, A. M., & Minotti, G. (2002). Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: Implications for cardiotoxicity of anticancer anthracyclines. Chemical Research in Toxicology, 15, 1179-1189.
6. Cartoni, A., Menna, P., Salvatorelli, E., Braghiroli, D., Giampietro, R., Animati, F., Urbani, A., Del Boccio, P., & Minotti, G. (2004). Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids : Novel function for ferrylmyoglobin? The Journal of Biological Chemistry, 279, 5088-5099.
7. Cairo, G., & Pietrangelo, A. (2000). Iron regulatory proteins in pathobiology. The Biochemical Journal, 352, 241-250.
8. Galy, B., Ferring, D., Benesova, M., Benes, V., & Hentze, M. W. (2004). Targeted mutagenesis of the murine IRP1 and IRP2 genes reveals context-dependent RNA processing differences in vivo. RNA, 10, 1019-1025.
9. Iwai, K., Drake, S. K., Wehr, N. B., Weissman, A. M., LaVaute, T., Minato, N., Klausner, R. D., Levine, R. L., & Rouault, T. A. (1998). Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: Implications for degradation of oxidized proteins. Proceedings of the National Academy of Sciences of the United States of America, 95, 4924-4928.
10. Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P., & Cairo, G. (2001). Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Research, 61, 8422-8428.
11. Corna, G., Santambrogio, P., Minotti, G., & Cairo, G. (2004). Doxorubicin paradoxically protects cardiomyocytes against ironmediated toxicity: Role of reactive oxygen species and ferritin. The Journal of Biological Chemistry, 279, 13738-13745.
12. Cairo, G., Recalcati, S., Pietrangelo, A., & Minotti, G. (2002). The iron regulatory proteins: Targets of free radicals and modulators of oxidative damage. Free Radical Biology & Medicine, 32, 1237-1243.
13. Cairo, G., Ronchi, R., Recalcati, S., & Minotti, G. (2003). Nitric oxide and peroxynitrite activate the Iron Regulatory Protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase. Biochemistry, 41, 7435-7442.
14. Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57, 727-741.
15. Minotti, G., Recalcati, S., Mordente, A., Liberi, G., Calafiore, A. M., Mancuso, C., Preziosi, P., & Cairo, G. (1998). The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB Journals, 12, 541-552.
16. Kwok, J. C., & Richardson, D. R. (2002). Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: The iron and copper complexes of anthracyclines decrease RNA-binding activity. Molecular Pharmacology, 62, 888-900.
17. Kwok, J. C., & Richardson, D. R. (2004). Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Molecular Pharmacology, 65, 181-195.
18. Cairo, G., Bernuzzi, F., & Recalcati, S. (2006). A precious metal: Iron, an essential nutrient for all cells. Genes and Nutrition, 1, 25-40.
19. Cusack, B. J., Gambliel, H., Musser, B., Hadjokas, N., Shadle, S. E., Charlier, H., & Olson, R. D. (2006). Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemotherapy and Pharmacology, 58, 517-526.
20. Sacco, G., Giampietro, R., Salvatorelli, E., Menna, P., Bertani, N., Graiani, G., Animati, F., Goso, C., Maggi, C. A., Manzini, S., & Minotti, G. (2003). Chronic cardiotoxicity of anticancer anthracyclines in the rat: Role of secondary alcohol metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. British Journal of Pharmacology, 139, 641-651.
21. Corna, R., Galy, B., & Cairo, G. (2006). IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice. Journal of Molecular Medicine, 84, 551-560.
22. Minotti, G., Cairo, G., & Monti, E. (1999). Role of iron in anthracycline cardiotoxicity: New tunes for an old song? FASEB Journals, 13, 199-212.
23. Galy, B., Ferring, D., & Hentze, M. W. (2005). Generation of conditional alleles of the murine Iron Regulatory Protein (IRP)-1 and -2 genes. Genesis, 43, 181-188.
24. Ladas, E. J., Jacobson, J. S., Kennedy, D. D., Teel, K., Fleischauer, A., & Kelly, K. M. (2004). Antioxidants and cancer therapy: a systematic review. Journal of Clinical Oncology, 22, 517-528.
25. Sokolove, P. M. (1994). Interactions of adriamycin aglycones with mitochondria may mediate adriamycin cardiotoxicity. International Journal of Biochemistry, 26, 1341-1350.
26. Gille, L., & Nohl, H. (1997). Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radical Biology & Medicine, 23, 775-782.
27. Olson, R. D., & Mushlin, P. S. (1990). Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB Journals, 4, 3076-3086.
28. Olson, R. D., Li, X., Palade, P., Shadle, S. E., Mushlin, P. S., Gambliel, H. A., Fill, M., Boucek, R. J. Jr, & Cusack, B. J. (2000). Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicology and Applied Pharmacology, 169, 168-176.
29. Gambliel, H. A., Burke, B. E., Cusack, B. J., Walsh, G. M., Zhang, Y. L., Mushlin, P. S., & Olson, R. D. (2002). Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochemical and Biophysical Research Communications, 291, 433-438.
30. Burke, B. E., Gambliel, H., Olson, R. D., Bauer, F. K., & Cusack, B. J. (2000). Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. British Journal of Pharmacology, 131, 1-4.
31. Menna, P., Minotti, G., & Salvatorelli, E. (2007). In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. Cell Biology and Toxicology, 23, 49-62.
32. Fiedler, W., Tchen, N., Bloch, J., Fargeot, P., Sorio, R., Vermorken, J. B., Collette, L., Lacombe, D., & Twelves, C. (2006). A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. European Journal of Cancer, 42, 200-204.
33. Salvatorelli, E., Guarnieri, S., Menna, P., Liberi, G., Calafiore, A., Mariggio', M. A., Mordente, A., Gianni, L., & Minotti, G. (2006). Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition. The Journal of Biological Chemistry, 281, 10990-11001.